

MEETING ROSTER
Oncologic Drugs Advisory Committee Meeting
February 8, 2011

FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Ralph Freedman, M.D., Ph.D.

Clinical Professor
Department of Gynecologic Oncology
The University of Texas
M.D. Anderson Cancer Center
Houston, TX 77230

William Kelly, D.O.

Professor of Medical Oncology and Urology
Thomas Jefferson University
Philadelphia, PA 19107

Patrick Loehrer, Sr., M.D.

Interim Director, Indiana University
Melvin and Bren Simon Cancer Center
Indiana University
Indianapolis, IN 46202

Brent Logan, Ph.D.

Associate Professor of Biostatistics
Division of Biostatistics
Medical College of Wisconsin
Milwaukee, WI 53226

Virginia Mason, R.N. (Consumer Representative)

Executive Director
Inflammatory Breast Cancer Research
Foundation
West Lafayette, IN 47906

Mikael Sekeres, M.D., M.S.

Associate Professor of Medicine
Staff
Cleveland Clinic Taussig Cancer Institute
Department of Hematologic Oncology and
Blood Disorders
Cleveland, OH 44195

Wyndham Wilson, M.D., Ph.D. (Chair)

Chief, Lymphoma Therapeutics Section
Metabolism Branch
Center for Cancer Research
National Cancer Institute
Rockville, MD 20892

INDUSTRY REPRESENTATIVE (Non-Voting)

Gregory Curt, M.D.

U.S. Medical Science Lead, Emerging Products
AstraZeneca Oncology
Garrett Park, MD 20896

MEETING ROSTER (continued)
Oncologic Drugs Advisory Committee Meeting
February 8, 2011

FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD

TEMPORARY VOTING MEMBERS

Frank Balis, M.D.

The Louis and Amelia Canuso Family Endowed
Chair for Clinical Research in Oncology
Director, Clinical Cancer Research
Center for Childhood Cancer Research
The Children's Hospital of Philadelphia
Philadelphia, PA 19104

Ralph D'Agostino, Ph.D.

Chair, Mathematics and Statistics Department
Boston University
Boston, MA 02215

Gary Lyman, M.D., M.P.H.

Professor of Medicine
Director, Comparative Effectiveness and
Outcomes Research,
Duke University School of Medicine
and the Duke Comprehensive Cancer Center
Durham, NC 27705

Silvana Martino, D.O.

Director, Breast Cancer Program
The Angeles Clinic and Research Institute
Santa Monica, CA 90404

Musa Mayer, M.S. (Patient Representative)

New York, NY 10024

Joanne Mortimer, M.D.

Director, Womens Cancers Program
Vice Chair Medical Oncology
Associate Director for Affiliate Programs
Professor, Division of Medical Oncology &
Experimental Therapeutics
City of Hope Comprehensive Cancer Center
Duarte, CA 91010

Ronald Richardson, M.D.

Consultant, Department of Medical Oncology
Mayo Clinic
Rochester, MN 55905

Malcolm Smith, M.D., M.P.H.

Associate Branch Chief for Pediatrics
Cancer Therapy Evaluation Program
National Cancer Institute
Rockville, MD 20852

GUEST SPEAKER (Non-Voting, Presenting Only)

Hilde Boone, Pharm, MSc

European Medicines Agency
Liaison Official at the US FDA

MEETING ROSTER (continued)
Oncologic Drugs Advisory Committee Meeting
February 8, 2011

FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD

FDA (Non-Voting)

Richard Pazdur, M.D.

Director

Office of Oncology Drug Products (OODP),
OND, CDER, FDA

Anthony J. Murgo, M.D., M.S.

Associate Director for Regulatory Science
OODP, OND, CDER, FDA

Paul G. Kluetz, M.D.

Medical Officer

Division of Drug Oncology Products (DDOP),
OODP, OND, CDER, FDA

Lee Pai-Scherf, M.D. (Erbix Only)

Medical Officer

Division of Biologic Oncology Products
DBOP, OODP, OND, CDER, FDA

Ruthann Giusti, M.D. (Bexxar & Vectibix Only)

Medical Officer

DBOP, OODP, OND, CDER, FDA

Suzanne Demko, P.A.-C. (Erbix, Bexxar &
Vectibix Only)

Medical Team Leader

DBOP, OODP, OND, CDER, FDA

Martin Cohen, M.D. (Clolar, Arranon &
Gleevec Only)

Medical Officer

DDOP, OODP, OND, CDER, FDA

John Johnson, M.D. (Clolar, Arranon & Gleevec
Only)

Medical Team Leader

DDOP, OODP, OND, CDER, FDA